Oragenics Partners with Receptor.AI to Expand Neurological Drug Pipeline Using AI-Powered Discovery

Oragenics, a clinical-stage biotech company focused on brain-targeted therapeutics, has announced a strategic collaboration with Receptor.AI, a drug profiling company leveraging artificial intelligence, to accelerate the development of new treatment candidates for a range of neurological and psychiatric conditions.

The partnership marks a pivotal step in Oragenics’ transformation from a single-asset company into a diversified neurological therapeutics developer. While continuing to advance its lead candidate, ONP-002, for concussion therapy, the company is now setting its sights on building a broader pipeline powered by AI.

Through this collaboration, Receptor.AI will use its proprietary computational models to analyze molecular structures acquired by Oragenics in 2023. The goal is to predict optimal receptor binding profiles, helping to identify compounds with potential therapeutic effects across diseases such as Alzheimer’s, Parkinson’s, PTSD, opioid addiction, and anxiety disorders.

“This partnership with Receptor.AI demonstrates our commitment to innovation at every level—from our proprietary intranasal delivery platform to the tools we use to identify promising therapeutic candidates,” said Janet Huffman, CEO of Oragenics. “By leveraging AI to guide our preclinical work, we believe we can focus resources on the most promising opportunities and potentially accelerate our path to identifying new treatments for a wide range of neuropsychiatric conditions.”

Receptor.AI’s predictive insights are expected to streamline Oragenics’ early-stage drug discovery efforts, reducing costs and increasing focus on molecules with the highest likelihood of success. If the AI-driven predictions are validated in the lab, Oragenics anticipates developing scientific data to support the advancement of multiple new candidates.

“At Receptor.AI, we are committed to enabling partners like Oragenics with advanced AI-driven insights that streamline drug discovery,” said Dr. Alan Nafiiev, CEO of Receptor.AI. “This collaboration reflects the practical value of applying AI to early-stage development to guide resources toward the most promising therapeutic opportunities.”

Oragenics is concurrently preparing to launch its Phase IIa clinical trial for ONP-002, an intranasal therapy for concussion, with trial initiation expected in the fourth quarter of 2025. The company sees this technology as a platform with broader applications.

“We believe our intranasal delivery platform has applications beyond concussion,” Huffman added. “By combining our delivery technology with AI-guided drug discovery, we’re hoping to build a sustainable, multi-asset company that can address unmet needs across the neurological disease spectrum.”

The partnership with Receptor.AI underscores Oragenics’ commitment to capital efficiency and long-term innovation in brain health therapeutics.